Results 231 to 240 of about 15,660,415 (298)

Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Bioengineered materials mediating the modulation of macrophage plasticity and inflammatory signals in the tumor microenvironment effectively remodel immunoregulatory states, boost antitumor immunity, and promote tissue repair, achieving synergistic therapeutic outcomes.
Jiayu Zhang   +16 more
wiley   +1 more source

Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK‐positive anaplastic large‐cell lymphoma

open access: yesHistopathology, Volume 89, Issue 6, Page 1031-1041, December 2026.
Poorly differentiated lung adenocarcinomas with concurrent anaplastic lymphoma kinase (ALK) and CD30 expression closely mimic ALK‐positive anaplastic large‐cell lymphoma, creating a significant diagnostic pitfall. Accurate classification requires comprehensive integration of clinical, radiologic, morphologic, immunophenotypic and molecular findings ...
Jietian Jin   +6 more
wiley   +1 more source

Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance. [PDF]

open access: yesNat Commun
Huang H   +15 more
europepmc   +1 more source

A PD1‐CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD‐L1 and CD137 Separately

open access: yesImmunology, Volume 179, Issue 4, Page 579-593, December 2026.
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia   +10 more
wiley   +1 more source

Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions

open access: yesCancer, Volume 132, Issue 22, 15 November 2026.
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Enrica Manzato   +5 more
wiley   +1 more source

Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia. [PDF]

open access: yesSci Rep
Hastak P   +16 more
europepmc   +1 more source

Regulation of IL‐13 Signaling by Retinoic Acid in Airway Epithelial Cells

open access: yesThe FASEB Journal, Volume 40, Issue 21, 15 November 2026.
Our proteomics and subsequent biochemical analyses reveal the effects of retinoic acid receptor (RAR) agonists, ATRA (pan‐RAR agonist), or CD1530 (RARγ agonist) in counteracting molecular changes induced by IL‐13 relevant to airway inflammation and remodeling, such as proteins involved in epithelial‐to‐mesenchymal transition (EMT) and extracellular ...
Vanshika Patel   +5 more
wiley   +1 more source

Granzyme B cleaves tenascin-C to release its C-terminal domain in rheumatoid arthritis. [PDF]

open access: yesJCI Insight
Aubert A   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy